Sol-Gel Reports Results of Twyneo in Two P-III Trials for Acne Vulgaris

 Sol-Gel Reports Results of Twyneo in Two P-III Trials for Acne Vulgaris

Sol-Gel Reports Results of Twyneo in Two P-III Trials for Acne Vulgaris

Shots:

  • The two P-III trials SGT-65-04 and SGT-65-05 involves assessing of Twyneo (qd) or vehicle cream in 858 patients in ratio (2:1) at 63 sites for 12 wks.
  • The P-III study results SGT-65-04 & SGT-65-05 trial success in IGA (38.5%, 25.4% vs 11.5%, 14.7%), absolute change from baseline of inflammatory lesion count (-21.6, -16.2 vs -14.8, -14.1), absolute change from baseline of non- inflammatory lesion count (-29.7, -24.2 vs -19.8, -17.4), well-tolerated
  • Twyneo (FD) is an antibiotic-free compromising combination of tretinoin 0.1% and microencapsulated benzoyl peroxide 3% cream based on microencapsulation technology platform with expected NDA submission in H2’20

Click here to read full press release/ article | Ref: GlobeNewswire | Image: Signbox

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post